A progressive neurological condition affecting movement, and increasingly understood as a disease with early origins in the gut and in cellular energy metabolism rather than the brain alone.
Conventional care centers on replacing dopamine, which addresses symptoms effectively for a period but does not engage the processes driving the underlying decline.
Research over the past decade has repeatedly implicated the gut — changes in the microbiome and in the enteric nervous system often precede motor symptoms by years.
Dr. Kellman's model treats the gut and brain as one interconnected system. Inflammation, immune imbalance, nutrient deficiency, hormone disruption, and microbiome dysfunction are each assessed as contributors.
Treatment supports mitochondrial function and neuroplasticity while reducing neuroinflammation, using targeted nutrients, microbiome repair, and technology-based therapies. The goal is to support function and quality of life alongside conventional neurological care.
No responsible clinician will promise reversal. What Dr. Kellman works toward is addressing the modifiable contributors — inflammation, microbiome disruption, nutrient and metabolic factors — to support function, resilience, and quality of life alongside standard neurological treatment.
Because microbiome and enteric nervous system changes are documented in Parkinson's, frequently appearing before movement symptoms. Assessing the gut gives access to a driver that a purely neurological workup does not examine.